Camizestrant Combination Cuts Risk of Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 Trial

Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6…

Read MoreCamizestrant Combination Cuts Risk of Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 Trial